Hyundai Motor India Q2 FY27: consolidated PAT down 24% YoY, margin below guidance
PAT -23.92% YoY · revenue +18.53% · margins compressing · miss vs street
₹20,696.06 Cr
+18.53% YoY
₹1,196.16 Cr
-23.92% YoY
5.72%
-3.2pp YoY
₹14.72
Hyundai Motor India's consolidated revenue from operations rose 18.5% YoY (and 26.7% QoQ) to ₹20,696 Cr, but consolidated PAT fell 23.9% YoY to ₹1,196 Cr even as it climbed 34.6% QoQ off a weak Q1 base. The YoY move is the one that matters: Street consensus (per a Business Standard Q2 preview citing Nuvama and other brokerages) had expected PAT of roughly ₹1,544 Cr, up ~12% YoY, on an EBITDA margin near 13.6% — the actual print missed on both counts, landing about 22-23% below the profit estimate with margin nearly 300 bps short of the expected level.
Q2 FY-2027 vs prior quarters
The gap sits squarely in the cost base. Consolidated EBITDA margin (PBT + finance costs + D&A, over revenue from operations) came in at ~10.6% this quarter versus 13.9% a year ago — a roughly 330 bps YoY compression — even though it improved sequentially from Q1's 9.25%. Net margin similarly fell to ~5.7% from 8.9% YoY. The driver is broad-based cost inflation outrunning revenue: cost of materials consumed rose 29% YoY to ₹15,731 Cr versus 18.5% revenue growth, employee costs rose 21.7%, and other expenses rose 24.8%. No exceptional items are disclosed in the statement, so this is an operating-cost story, not a base-effect one.
The stock went into the print at ₹1,875.1, down 11.3% over the past month of trading.
For context: revenue is at a 6-quarter high.
Management guides for robust 8-10% volume growth in both domestic and export markets for FY'27, aiming to significantly outpace the industry. This growth will be driven by two new nameplate launches—a localized mass-market compact EV and a mid-size ICE SUV—supported by an aggressive capex of INR 7,500 crores. Despite a
— This quarter: missed
Against management's own FY27 guidance from the Q4 FY26 concall — 8-10% volume growth and an 11-14% EBITDA margin band — the margin metric is running below the guided floor for a second consecutive quarter (9.25% in Q1, ~10.6% now), even as it trends in the right direction sequentially. Volume looks healthier: the company logged its highest-ever monthly domestic sales of 77,916 units in September 2026, within this quarter, consistent with revenue growth running well ahead of the lower end of the guided volume range. Standalone results track closely with consolidated — PAT of ₹1,188.6 Cr on revenue of ₹20,191 Cr, EPS ₹14.63 versus ₹14.72 consolidated — indicating the subsidiaries (engineering and insurance broking units) added only a modest net uplift this quarter.
W1
EBITDA margin trajectory toward the guided 11-14% FY27 band — currently ~10.6% in Q2 after 9.25% in Q1
W2
Cost of materials consumed as a share of revenue (~76% this quarter vs ~71% a year ago) — whether management's calibrated pricing and cost optimization narrow this
W3
Volume growth pace versus the guided 8-10% FY27 target, following September's record 77,916-unit month
Filing reported in ₹ Millions, converted to ₹ Crore (÷10); sub-₹0.02 Cr gaps are rounding. No exceptional/one-off items disclosed in either period, so no raw-vs-adjusted PAT split was needed. No management press release was available in our records for this result.
Margin recovery and momentum convergence — watching Q2 execution
After a margin squeeze in Q1 (9.3% EBITDA), Hyundai India expects to recover toward its 11–14% FY27 guidance as sales momentum holds. The Pune plant ramp and product launches set up medium-term earnings lift.
The Setup: Margin Pinch into Recovery
Q1 FY27 landed with a 400 bps EBITDA margin hit—9.3% vs 13.3% a year ago—driven by input cost inflation that outpaced a 1% price adjustment. Management flagged the hit as temporary and committed to 11–14% EBITDA for the full year. Q2 is the proof point. Three levers are now in motion: a 1% price hike effective September, cost optimization and operating leverage from rising volumes, and early recovery of impacted production (management reports most recovery achieved in July itself). The Street expects margin to improve toward the 11–12% range in Q2, contingent on input costs stabilizing and price realization holding.
~11–12%
Guided 11–14% FY27; Q1 was 9.3%. Recovery on track if input costs stable.
~8–12%
Sales momentum strong (Aug +23.6%, Sep +10.8% YoY). Export recovery slower.
1% hike live
Sep 2026 onward. Key to bridging input cost delta and margin recovery.
3.28%
Down 214 bps QoQ (from FY27 Q1). Watching for stabilization or outflows.
What Matters: Volume, Margin, Guidance Reaffirmation
A strong quarter would show: EBITDA margin hitting 11–12% or better; domestic volume growth confirming 8–10% trajectory; PAT recovering to ~₹9–10 Bn range (vs ₹8.9 Bn in Q1); no downgrades to FY27 guidance despite near-term cost headwinds. A weak quarter would flag: EBITDA margin stuck below 10% (implying input inflation/price realization miss); volume growth slowing below 5%; guidance cuts or warnings on margin recovery path; signs of demand softening or market share loss.
On Track?
The company is tracking its guidance trajectory, though not without friction. Q1 showed the margin pinch earlier than expected, but management's rapid response (price hike, production recovery in July ahead of schedule) suggests execution discipline. The 8–10% FY27 volume growth is within reach given domestic momentum (Jul–Sep sales averaging +20% YoY), though export weakness (Q1 down 20%) is a watch item. Hyundai's newly inaugurated Pune plant (₹11,000 Cr capex) and the USD 15.5 Bn Group commitment through 2032 position the company for medium-term earnings accretion, but Q2 results will reset confidence in near-term margin recovery.
What the Street Says
Since Last Quarter
1 · Pune Plant Inauguration (Oct 14)
Hyundai formally opened its new Industry 4.0 and AI-enabled manufacturing facility in Maharashtra, with initial annual capacity of 330,000 units. This ₹11,000 Cr capex marks a pivot toward higher-margin EVs and SUVs in the medium term.
2 · USD 15.5 Bn Group Investment (Oct 13)
Hyundai Motor Group committed USD 15.5 Bn for India's automotive ecosystem through 2032. Strategic signal of long-term confidence; capex will likely weigh on near-term FCF but support earnings growth from FY28.
3 · Record Monthly Sales (Sep 2026)
77,916 units total (+10.8% YoY), highest single month on record. Domestic sales 57,166 units. Signals strong underlying demand and validates management's recovery commentary.
4 · Product Pipeline (BAYON SUV, Sep 14)
Hyundai announced the Hyundai BAYON SUV, expanding its portfolio in the high-growth intelligent SUV segment. Launch expected soon; likely to contribute to FY27/FY28 volume mix upside.
5 · 1% Price Hike (Aug 19, effective Sep 2026)
Announced pre-emptively to offset input and commodity cost inflation. Critical to margin recovery in Q2 onwards; realization will be key watch.
6 · FII Selling Pressure
FII ownership slipped from 5.42% (Q4 FY26) to 3.28% (Q1 FY27), a 214 bps outflow. Likely driven by sector rotation and near-term margin concerns. Watch for stabilization post-Q2 results.
7 · 30th AGM (Aug 26, 2026)
Routine annual meeting held. Dividend paid. No material corporate actions flagged.
Hyundai India stands at an inflection: Q1's margin squeeze was real and front-loaded, but management's rapid execution (production recovery, price hikes, cost discipline) signals confidence in a rebound. Q2 results on Oct 28 will answer three questions: (1) Is margin recovery on track to 11–12% or stuck? (2) Does volume growth hold at 8–10%+ pace? (3) Is FY27 guidance robust or at risk? The Pune plant, new SUV launches, and Group capex support a multi-year earnings cycle, but near-term confidence rides on Q2 delivery.
Three to watch on result day: (1) EBITDA margin print and guidance commentary — the margin recovery narrative is make-or-break for near-term sentiment. (2) Export segment recovery — Q1 exports fell 20% YoY; a rebound is needed to confirm FY27 volume growth. (3) Operating cash flow and capex deployment — with USD 15.5 Bn committed, the shape of capex will frame medium-term ROI and FCF visibility.